

G42 Healthcare Partnership Commences Operation

- **First microbiome reports in partnership with G42 Healthcare delivered to users in the United Arab Emirates today**
- **Partnership signed in February 2022 enabled a gut microbiome test to be developed and deployed for G42 Healthcare, a leading health-tech company**
- **G42 Healthcare offers healthcare services and consumer genomics services across the Gulf Cooperation Council region to unlock personalised and preventative care**

Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”) is pleased to announce that G42 Healthcare’s first microbiome reports, powered by Microba’s Analysis Platform, were delivered to users in the United Arab Emirates today.

Leveraging Microba’s Analysis Platform, the partnership signed with G42 Healthcare in February 2022 has enabled a gut microbiome testing service to be developed by G42 Healthcare which will be available to individuals in the United Arab Emirates, Saudi Arabia, Bahrain, Kuwait, Oman and Qatar.

G42 Healthcare is progressing to a full market launch to offer a range of wellbeing and gut health solutions to customers alongside their personal genomics tests. This is a first-to-market local offering developed for the territory to deliver true personalisation for consumers across the Gulf Cooperation Council (GCC) region.

Commenting on the milestone, **Microba CEO Dr Luke Reid** said: “We are pleased to see our testing technology being delivered to customers in the GCC region via our market-leading distribution partners. This demonstrates how Microba’s scalable platform can deliver microbiome testing products into new markets.”

This announcement has been authorised for release by the Board.

For further information, please contact:

Dr Luke Reid
Chief Executive Officer
E: Luke.Reid@microba.com

Simon Hinsley
Investor / Media Relations
E: simon@nwrcommunications.com.au
T: +61 401 809 653

About G42 Healthcare

G42 Healthcare, a leading health-tech company, is on a mission to develop a world-class healthcare sector in the UAE and beyond, by harnessing data and advanced medical technologies to unlock the potential of personalised and preventive care and transforming the traditional healthcare ecosystem.

About Microba Life Sciences Limited

Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions.

For more information visit: www.microba.com

Microba encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.